Item 9 Labs Corp (INLB) Fair Value & Analysis
Healthcare · US · Market cap $10.2K
Fair value as of: Jun 26, 2026
Analysis
Item 9 Labs Corp (INLB) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Item 9 Labs Corp (INLB) undervalued?
What is the fair value of INLB?
What is the quality score of INLB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.